<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049021</url>
  </required_header>
  <id_info>
    <org_study_id>ECT Schizo</org_study_id>
    <nct_id>NCT02049021</nct_id>
  </id_info>
  <brief_title>Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia</brief_title>
  <acronym>SSURECT</acronym>
  <official_title>Pilot Double Blind, Placebo Controlled and Randomized Study to Assess Electroconvulsive Therapy Efficacy as Augmenting Strategy to Clozapine in Super-refractory Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: In spite of recent advances in schizophrenia treatment, 30% of patients still
      do not respond properly to antipsychotic therapy. These patients are considered
      treatment-resistant or refractory, and the best choice for them is clozapine. However, even
      supported by the literature as the best known antipsychotic in terms of efficacy and rates of
      response, a considerable number of patients will still not respond to this treatment,
      remaining symptomatic and dysfunctional. These patients are classified as super-refractory
      (clozapine-resistent). In these cases, augmenting strategies are necessary, and some have
      been in use: typical and atypical antipsychotics, mood stabilizers, antidepressants and
      electroconvulsive therapy (ECT). Some studies have favored ECT, but no definitive conclusion
      has been drawn.

      Objective: Test the electroconvulsive therapy efficacy and safety as augmenting strategy to
      clozapine-resistant patients, as compared to placebo (sham ECT).

      Methods: This is a pilot double blind, placebo controlled and randomized study to assess
      electroconvulsive therapy efficacy as augmenting strategy to clozapine in super-refractory
      schizophrenia. The ECT treatment will be delivered with either a MECTA SPECTRUM 5000Q or
      4000Q device, and the procedure is under general anesthesia and monitorization, after
      informed consent. The Hospital will follow national protocols and regulations on ECT. Sham
      ECT consists in habitual patient preparation and sedation, without stimulation. Patients that
      fit inclusion criteria will have their clozapine blood levels dosed and undergo structured
      assessments at baseline, after 6 treatments and at the end of the cycle of 12 ECT sessions
      (thrice a week protocol). The assessments will be based on CGI (Clinical Global Impression)
      and PANSS (Positive and Negative Syndrome Scale) scales. All medication will be maintained,
      except lithium carbonate.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS change from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Structured assessments will be done at baseline, and at the end of the cycle of 12 ECT sessions (thrice a week protocol). The assessments will be based on PANSS (Positive and Negative Syndrome Scale). Changes from Baseline on this scale will be documented after a 4 weeks period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PANSS change from baseline</measure>
    <time_frame>2 weeks</time_frame>
    <description>Structured assessments will be done at baseline, and at the end of the cycle of 6 ECT sessions (thrice a week protocol). The assessments will be based on PANSS (Positive and Negative Syndrome Scale). Changes from Baseline on this scale will be documented after a 2 week period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI change from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinical Global Impression will be assessed as well, along with PANSS scale, and changes compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI change from baseline</measure>
    <time_frame>2 weeks</time_frame>
    <description>Clinical Global Impression will be assessed as well, along with PANSS scale, and changes compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory Schizophrenia</condition>
  <condition>Super Refractory Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Electroconvulsive Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in use of clozapine randomized to receive ECT treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM ECT</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receiving clozapine randomized to sham ECT (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MECTA SPECTRUM 5000Q ECT</intervention_name>
    <arm_group_label>Electroconvulsive Therapy</arm_group_label>
    <other_name>ECT</other_name>
    <other_name>Electrochock</other_name>
    <other_name>electroconvulsive therapy device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham ECT</intervention_name>
    <description>Sedation using propofol or etomidate and usual ECT preparation (no stimulation)</description>
    <arm_group_label>SHAM ECT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia or schizoaffective disorder (DSM-IV-TR);

          -  Ages between 18 and 55 years old, both genders;

          -  Must be using adequate contraception if a fertile woman;

          -  Must be on clozapine treatment for at least 6 months, with or without augmenting
             strategies;

          -  Must be clozapine-resistent (super-refractory patient), defined by a CGI-severity ≥ 4,
             PANSS total score ≥ 60 and at least 4 items of the positive subscale ≥ 4 at baseline.

        Exclusion Criteria:

          -  Clinical somatic disease not stabilized in the three months preceding the study;

          -  Other Axis I disorders (DSM-IV-TR);

          -  Laboratory tests with significantly abnormal values that persist for more than two
             weeks;

          -  Lack of permanent residence during the study period;

          -  History of poor treatment adherence.

          -  History of ECT use in the past six months that precede the start of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélio Elkis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helio Elkis, MD,PhD</last_name>
    <phone>+55-1126617581</phone>
    <email>helkis@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debora L Melzer-Ribeiro, MD</last_name>
    <phone>+55-11999415282</phone>
    <email>deboramelzer@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Psychiatry - Clinics Hospital - University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helio Elkis, Md PhD</last_name>
      <phone>+55-11-2661-7322</phone>
    </contact>
    <contact_backup>
      <last_name>Debora Melzer, MD</last_name>
      <phone>+551126616525</phone>
      <email>deboramelzer@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Helio Elkis, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.ipqhc.org.br/</url>
    <description>Institute of Psychiatry - University of Sao Paulo</description>
  </link>
  <link>
    <url>http://www.psiquiatriafmusp.org.br/departamento/</url>
    <description>Department of Psychiatry - University of Sao Paulo Medical School</description>
  </link>
  <reference>
    <citation>Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2007 Sep;30(3):511-33. Review.</citation>
    <PMID>17720034</PMID>
  </reference>
  <reference>
    <citation>Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, Paplos KG, Soldatos CR. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol. 2006 Jan-Feb;29(1):52-6. Review.</citation>
    <PMID>16518135</PMID>
  </reference>
  <reference>
    <citation>Kho KH, Blansjaar BA, de Vries S, Babuskova D, Zwinderman AH, Linszen DH. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study. Eur Arch Psychiatry Clin Neurosci. 2004 Dec;254(6):372-9. Epub 2004 Nov 12.</citation>
    <PMID>15538604</PMID>
  </reference>
  <reference>
    <citation>Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56. Review.</citation>
    <PMID>15000267</PMID>
  </reference>
  <reference>
    <citation>Miller A, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004 Apr;65(4):500-8. Review.</citation>
    <PMID>15119912</PMID>
  </reference>
  <reference>
    <citation>Tang WK, Ungvari GS. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):373-9.</citation>
    <PMID>12691772</PMID>
  </reference>
  <reference>
    <citation>Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2002;(2):CD000076. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD000076.</citation>
    <PMID>12076380</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Helio Elkis</investigator_full_name>
    <investigator_title>MD, PhD ; Associated Professor of the Departament of Psychiatric</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>electroconvulsive therapy</keyword>
  <keyword>refractory Schizophrenia</keyword>
  <keyword>super refractory schizophrenia</keyword>
  <keyword>clozapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

